Changes regarding the Spanish Common Package of Benefits

16

Nov 2022

Earlier this year, the Commission of Benefits, Insurance, and Financing made several agreements in cardiovascular and endocrine fields, which were subsequently approved by the Interterritorial Council of the National Health System (CISNS). On October 28, 2022, several Resolutions of the General Directorate of the Common Package of Benefits of the National Health and Pharmacy System in this regard were published concerning the use of the system for percutaneous repair of the mitral valve with clip, prioritization of patients with type 2 diabetes mellitus for the provision of glucose monitoring systems, the use of glucose monitoring system with sensors (flash type) for type 1 diabetes mellitus in childhood and adolescence.

The following key conclusions were provided in these Resolutions respectively:

  • It was outlined that the system for percutaneous repair of the mitral valve with clip should be kept in the Common Package of Benefits of the National Health System under the same conditions as in the monitoring study protocol. The Resolution outlined the patient criteria that must be met, as well as the information on the minimum requirements the hospitals should meet to be eligible to perform this service. This decision was based on the monitoring study by the Basque Office for Health Technology Assessment (OSTEBA);
  • Prioritization criteria for patients with type 2 diabetes mellitus that undergo intensive insulin therapy and require at least six digital punctures per day for self-monitoring of blood glucose, to whom it is necessary to provide glucose monitoring systems were outlined for the following periods: the second half of 2022 and the first half of 2023 (with the commitment to start in the second half of 2022), the first half of 2023, the second half of 2023, throughout 2024. As an example, for the first period mentioned above, the following patient categories are specifically included: patients with visual impairment, functional limitations, disability, dependence, or cognitive impairment that limits or prevents them from performing digital punctures or recognizing, expressing, or acting in a situation of hypoglycemia; patients with a history of severe hypoglycemia defined as those that require health care or help from a third person for its solution (one episode or more in the last two years); patients under 18 years of age; pregnant women or women in the process of pregnancy planning;
  • Suffering inadvertent hypoglycemia is no longer considered an exclusion criterion for the provision of glucose monitoring systems using sensors (flash type) for type 1 diabetes mellitus in childhood and adolescence. Other inclusion and exclusion criteria for this indication have not changed.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

16

Mar 2023

In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.

Read more

14

Mar 2023

The Ministry of Health has commissioned the Agency for Health Quality and Assessment of Catalonia (AQuAS) to develop, with the collaboration of the various agencies that make up the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS), a specific methodological framework for the evaluation of digital health technologies that would allow a comprehensive assessment of this type of technology. The methodological framework is in the final phase of development.

Read more

13

Mar 2023

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 3844 of March 02, 2023, Tuscany Regional Healthcare has published assessments of four medical devices in the cardiovascular and neurovascular treatment areas.

Read more

15

Feb 2023

In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields.

Read more

03

Feb 2023

On January 30, 2023, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2022. The medical technologies belonging to the cardiovascular, eHealth, gastrointestinal, neuromodulation, neurovascular, peripheral vascular, orthopedic, and other technology groups obtained positive status 1.

Read more